Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial
Introduction About 25% of patients with COVID-19 develop acute respiratory distress syndrome (ARDS) associated with a high release of pro-inflammatory cytokines such as interleukin-6 (IL-6). The aim of the SARICOR study is to demonstrate that early administration of sarilumab (an IL-6 receptor inhib...
Main Authors: | Antonio Luque-Pineda, Julian Torre-Cisneros, M Ángeles Esteban-Moreno, Rafael León López, Sheila Cárcel Fernández, Laura Limia Pérez, Alberto Romero Palacios, María Concepción Fernández-Roldán, Eduardo Aguilar Alonso, Inés Pérez Camacho, Nicolás Merchante, Julián Olalla, Marta Santos |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/10/11/e039951.full |
Similar Items
-
Sarilumab: patient-reported outcomes in rheumatoid arthritis
by: Crotti C, et al.
Published: (2018-08-01) -
Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
by: Raimondo MG, et al.
Published: (2017-05-01) -
Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
by: Paul Emery, et al.
Published: (2020-11-01) -
New possibilities of drug therapy for rheumatoid arthritis: focus at sarilumab
by: D. E. Karateev, et al.
Published: (2019-11-01) -
Sarilumab use in severe SARS-CoV-2 pneumonia
by: Elisa Gremese, et al.
Published: (2020-10-01)